DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury

Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy

(2015) Eunsoo Jung et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen

(2014) Keizo Kanasaki et al.   DIABETES

Prevention of Obesity-Induced Renal Injury in Male Mice by DPP4 Inhibition

(2014) Ravi Nistala et al.   ENDOCRINOLOGY

Linagliptin Blocks Renal Damage in Type 1 Diabetic Rats by Suppressing Advanced Glycation End Products-Receptor Axis

(2014) S. Nakashima et al.   HORMONE AND METABOLIC RESEARCH

Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy

(2014) Yuliya Sharkovska et al.   JOURNAL OF HYPERTENSION

DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat

(2014) Ravi Nistala et al.   Obesity

Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes

(2013) Ryo Kodera et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls

(2013) D. J. Drucker   DIABETES

Fibroblast Growth Factor 21 Improves Insulin Resistance and Ameliorates Renal Injury indb/dbMice

(2013) H. W. Kim et al.   ENDOCRINOLOGY

Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus

(2013) Hiroko Mori et al.   Journal of Diabetes Investigation

Evaluation of the Pharmacokinetics, Food Effect, Pharmacodynamics, and Tolerability of DA-1229, a Dipeptidyl Peptidase IV Inhibitor, in Healthy Volunteers: First-in-Human Study

(2012) Tae-Eun Kim et al.   CLINICAL THERAPEUTICS

DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy

(2012) Markus L. Alter et al.   KIDNEY & BLOOD PRESSURE RESEARCH

The effect of glucagon-like peptide 1 on cardiovascular risk

(2012) Jacob Sivertsen et al.   Nature Reviews Cardiology

Discovery of DA-1229: A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

(2011) Heung Jae Kim et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Incretin-based therapies - review of the physiology, pharmacology and emerging clinical experience

(2011) J. H. Martin et al.   INTERNAL MEDICINE JOURNAL

DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes

(2011) Mi-Kyung Kim et al.   LIFE SCIENCES

A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis

(2010) Jae Min Cho et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Expanding the Dipeptidyl Peptidase 4-Regulated Peptidome via an Optimized Peptidomics Platform

(2010) Arthur D. Tinoco et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Adriamycin nephropathy: A model of focal segmental glomerulosclerosis

(2010) VINCENT WS LEE et al.   NEPHROLOGY

Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model

(2009) Kunio Hirata et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS